Copyright
©The Author(s) 2016.
World J Gastroenterol. Feb 28, 2016; 22(8): 2424-2433
Published online Feb 28, 2016. doi: 10.3748/wjg.v22.i8.2424
Published online Feb 28, 2016. doi: 10.3748/wjg.v22.i8.2424
Table 2 The success rate of Helicobacter pylori eradication therapy in remnant stomach
| Ref. | No. of patients | Regimen of eradication | Success rate, n (%) |
| Matsukura et al[42] 2003 | 20 | Dual therapy | 14 (70.0) |
| Lansoprazole 60 mg, AMPC 1500 mg for 2 wk | |||
| 20 | Triple therapy | 18 (90.0) | |
| Lansoprazole 60 mg, AMPC 1500 mg, CAM 800 mg daily for 1 wk | |||
| Onoda et al[52] 2005 | 33 | Triple therapy | 30 (90.9) |
| Rabeprazole 20 mg, AMPC 1500 mg, CAM 800 mg daily for 1 wk | |||
| Kim et al[53] 2008 | 61 | Triple therapy | 53 (86.9) |
| Rabeprazole 20 mg, AMPC 2000 mg, CAM 1000 mg daily for 1 wk |
- Citation: Ohira M, Toyokawa T, Sakurai K, Kubo N, Tanaka H, Muguruma K, Yashiro M, Onoda N, Hirakawa K. Current status in remnant gastric cancer after distal gastrectomy. World J Gastroenterol 2016; 22(8): 2424-2433
- URL: https://www.wjgnet.com/1007-9327/full/v22/i8/2424.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i8.2424